French Registry: Late Gadolinium Enhancement in Hypertrophic Cardiomyopathy

This study aims to create a registry of patients with hypertrophic cardiomyopathy, a condition characterized by excessive thickening of the heart muscle. This disease can sometimes lead to serious complications. Currently, the prognosis of these patients is mainly determined by clinical and echocardiographic parameters. Detection of myocardial fibrosis using cardiac MRI enables better risk stratification for these patients.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Cardiomyopathy Aortic Stenosis, Subvalvular Aortic Valve Disease Aortic Valve Stenosis Cardiomyopathies Cardiomyopathy, Hypertrophic Cardiovascular Diseases Heart Diseases Heart Valve Diseases Hypertrophic Cardiomyopathies

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Age ≥ 18 years
Ability to provide informed consent
HCM diagnosis referred for CMR assessment.

Exclusion criteria

Patients unable to provide informed consent,
Patients with a history of ischemic cardiomyopathy or myocarditis.

Treatment and study plan

Primary outcomes

To build a score using the "LGE granularity" concept for all-cause mortality prediction in HCM patients.

Time frame: From Baseline to 5 years

All-cause mortality using the electronic French National Registry of Death (Institut National de la Statistique et des Etudes Economiques, INSEE registry).

Study contacts

Contact information is provided by the study sponsor or research team.

Théo PEZEL, Dr

CONTACT

[email protected]

+33 6 68 72 24 89

Sponsors and collaborators

Lead sponsor

Assistance Publique - Hôpitaux de Paris

Other

Registry information

Official study title

Retrospective French Registry of Cardiovascular Magnetic Resonance Late Gadolinium Enhancement in Patients With Hypertrophic Cardiomyopathy

Acronym: HCM-LGE

Important dates

Study start: 2026
Primary completion: 2031
Study completion: 2036
First posted: Feb 23, 2026
Registry last updated: Feb 23, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Recruiting